Jazz Pharma Q1 Revenue Jumps 19%, Beats Estimates; Reaffirms FY Outlook
JAZZ has more than doubled off its 52-week low of $97.5.
Summary
Jazz Pharmaceuticals reported robust first-quarter results, significantly exceeding analyst expectations for both revenue and adjusted EPS. Revenue surged 19% year-over-year to $1.07 billion, comfortably beating the $976.56 million consensus, while adjusted EPS reached $6.34, well above the $4.57 estimate. This strong performance, driven by robust sales growth in key products like Xywav, Epidiolex, and Zepzelca, provides a positive contrast to the net loss reported in the 2025 10-K. The company also reaffirmed its full-year 2026 revenue guidance, signaling confidence in continued operational strength. Traders will likely view these results as a strong indicator of positive momentum, especially following the recent news regarding the reclassification of cannabis-based medicines, which could further benefit products like Epidiolex. The anticipated U.S. launch of zanidatamab by August 2026 remains a key future catalyst.
At the time of this announcement, JAZZ was trading at $223.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.3B. The 52-week trading range was $97.50 to $212.57. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.